Lycera Corporation

Gary Glick’s fourth biotechnology firm, Scorpion Therapeutics , emerged from stealth mode on 26 October with $108m to develop small molecules that are safer, more tolerable and provide deeper, more d

Celgene Corp. 's aggressive deal-making strategy could pay off in a big way over the next several years, bringing in billions of dollars in annual sales from new drugs to diversify revenue beyond its

A few billion dollars paid over several years in the grand scheme of Bristol-Myers Squibb Co. 's massive immuno-oncology portfolio isn't such a huge thing, but more than $2bn in potential milestone

The table records clinical developments using data from Informa Pharma Intelligence’s Biomedtracker. It lists drugs for which an important event was recorded between Dec. 2 and Dec. 8, 2016, divided b